硫酸氢氯吡格雷的手性纯度:为什么溶液放几天,对映体就能长出来Chiral Purity of Clopidogrel Bisulfate: Why the Enantiomer Grows Out of Solution Within Days
硫酸氢氯吡格雷↗(CAS 120202-66-6)是噻吩吡啶类抗血小板前药,分子里只有一个手性中心——C7,一个同时挂着 2-氯苯基、甲酯和四氢吡啶环的苄位碳。单看这一点,很多人会把它归到「手性负担很轻」的一类:一个中心,拆开就行。问题在于这个碳恰好同时挨着芳环和酯基,α-氢酸性被拉高,碱一来就能烯醇化。对映体不只是拆分残留,它还会在成品溶液里慢慢长出来。
Clopidogrel bisulfate↗ (CAS 120202-66-6) is a thienopyridine antiplatelet prodrug with a single stereocentre, C7, a benzylic carbon carrying a 2-chlorophenyl group, a methyl ester and a tetrahydropyridine ring. On that basis alone many would file it as a light chiral burden: one centre, resolve it and you are done. The problem is that this carbon happens to sit next to both an aromatic ring and an ester, raising the acidity of its α-hydrogen so that any base enolises it. The enantiomer is not merely resolution residue; it also grows slowly in the finished product solution.
Note: product names shown in red (marked with ↗) are clickable. Click to open the product page for structure, CAS number, purity and lead time.
一、品种定位:一个手性中心,两种对映体,一种上市1. Positioning: one stereocentre, two enantiomers, one marketed
关键要点Key points
- (S)-(+) 对映体有抗血小板活性,(R)-(−) 无活性,高剂量下在动物中可致惊厥,因此被当作杂质控制;上市品是单一对映体The (S)-(+) enantiomer carries antiplatelet activity while (R)-(−) is inactive and can cause convulsions in animals at high dose, so it is controlled as an impurity; the marketed product is the single enantiomer[1]。
- 消旋是非酶促的:37 °C、0.1 mol/L 磷酸盐缓冲液中半衰期 7–12 天,随 pH 变化;大鼠体内可见 4–8% 的 (R)-羧酸Racemisation is non-enzymatic: in 0.1 mol/L phosphate buffer at 37 °C the half-life is 7–12 days and varies with pH; 4–8% of the (R)-carboxylic acid is seen in rats[2]。
- 消旋发生在酯基完整的分子上:(S)-羧酸在同样缓冲液中 45 天构型稳定Racemisation occurs in the molecule with an intact ester: the (S)-carboxylic acid is configurationally stable in the same buffer for 45 days[2]。这与「酯水解和消旋是两条通道」的判断一致。. This is consistent with the judgement that ester hydrolysis and racemisation are two separate channels.
- 本目录收录该品种 111 条,83 个编号杂质,消旋体与 R-异构体分别单列,系统适用性用消旋体而不是单一对映体This catalogue holds 111 entries for this substance with 83 numbered impurities, listing the racemate and the R-enantiomer separately, and system suitability uses the racemate rather than a single enantiomer[3]。
氯吡格雷Clopidogrel↗ C16H16ClNO2S,分子量 321.8,是前药,经 CYP2C19 两步氧化生成活性代谢物才抑制 P2Y12。手性中心在 C7:这个碳连着 2-氯苯基、甲氧羰基、四氢吡啶环的氮亚甲基和一个氢,四个取代基不同,所以是手性碳;它同时是苄位碳与酯的 α-碳,氢的酸性被两个基团一起拉高——这是后面所有问题的化学根源。S, molecular weight 321.8, is a prodrug that requires two CYP2C19-mediated oxidations to form the active metabolite that inhibits P2Y12. The stereocentre is C7: that carbon bears a 2-chlorophenyl group, a methoxycarbonyl group, the nitrogen methylene of the tetrahydropyridine ring and a hydrogen, four different substituents, making it a stereogenic carbon. It is simultaneously a benzylic carbon and the α-carbon of an ester, and the two groups together raise the acidity of its hydrogen, which is the chemical root of every problem discussed below.
成盐形式是硫酸氢盐。选择它的理由之一是溶解度:中性水中几乎不溶,pH 1 时易溶The salt form is the bisulfate. One reason for choosing it is solubility: practically insoluble in neutral water, readily soluble at pH 1[1],胃内环境正好。这也意味着它在制剂里以盐的形式存在,而在溶液里(比如溶出介质、含量测定供试液)会同时面对水解与消旋两条通道。, which matches the gastric environment. This also means it exists as the salt in the formulation while in solution (dissolution media, assay sample solutions) it faces both hydrolysis and racemisation at once.
本目录收录硫酸氢氯吡格雷相关条目 This catalogue contains 111 条(含原料药本体),编号杂质 83 个,编号覆盖 2–140,另含游离碱、盐酸盐、苯磺酸盐与 L-樟脑磺酸盐等形态。《中国药典》与《欧洲药典》《美国药典》均收载本品种 entries for clopidogrel bisulfate (including the drug substance itself), 83 numbered impurities covering numbers 2–140, plus the free base, hydrochloride, besylate and L-camphorsulfonate forms. The Chinese, European and United States Pharmacopoeias all monograph this substance[3]。

二、对映体的两个来源,只有一个能靠结晶解决2. Two sources of the enantiomer, only one of which crystallisation can fix
项目里讨论「R 异构体超标」,通常默认它是拆分不完全的残留。这只说对了一半。When a project discusses an out-of-specification R-enantiomer, the default assumption is incomplete resolution. That is only half the story.
来源一:拆分与结晶。Source one: resolution and crystallisation.本品工业上通过形成樟脑磺酸盐拆分对映体,本目录就收录了「 The substance is resolved industrially through formation of the camphorsulfonate salt, and this catalogue lists the intermediate form 氯吡格雷 L-樟脑磺酸clopidogrel L-camphorsulfonate↗」(CAS 120202-68-8)这个中间形态。拆分不完全、母液夹带、重结晶次数不足,都会把 (R) 带进成品。这一类问题靠工艺解决:增加重结晶、优化晶种、控制母液残留。(CAS 120202-68-8). Incomplete resolution, mother-liquor carry-over and too few recrystallisations all carry (R) into the product. This class is solved by process: more recrystallisation, better seeding, control of mother-liquor residues.
来源二:溶液中的非酶促消旋。Source two: non-enzymatic racemisation in solution.这一类靠工艺解决不了。公开研究在 37 °C、0.1 mol/L 磷酸盐缓冲液中观察到氯吡格雷自发消旋,半衰期 7–12 天并随 pH 变化;改用离体肝细胞也测不到酶促消旋,说明这是纯化学过程 This class cannot be fixed by process. Published work observed spontaneous racemisation of clopidogrel in 0.1 mol/L phosphate buffer at 37 °C with a half-life of 7–12 days that varies with pH, and isolated hepatocytes showed no enzymatic racemisation, indicating a purely chemical process[2]。同一项研究里,(S)-羧酸在缓冲液中 45 天构型稳定. In the same study the (S)-carboxylic acid was configurationally stable in buffer for 45 days[2]——也就是说,消旋要求酯基还在,一旦水解成酸,手性中心就锁住了。: in other words, racemisation requires the ester to be intact; once hydrolysed to the acid, the stereocentre is locked.
半衰期以「天」计,决定了风险落在哪类操作上。以小时计的操作——称样、配制、进样、序列过夜——只走完半个到一个半衰期的零头;以天计的操作——稳定性留样、溶出液放置、方法验证的溶液稳定性、留样复测——就会实打实地改变手性纯度。这也解释了另一项研究的结果:临时配制的口服混悬液冷藏两个月几乎无转化,室温放置则能测到少量 (R) 增加A half-life measured in days determines which operations carry the risk. Operations measured in hours, such as weighing, preparation, injection and overnight sequences, consume only a fraction of a half-life, whereas operations measured in days, such as stability retention samples, standing dissolution samples, solution stability during method validation and retesting of retained samples, genuinely change the chiral purity. This also explains another study's result: an extemporaneously prepared oral suspension showed almost no conversion after two months refrigerated, while storage at room temperature produced a measurable increase in (R)[4]。温度与时间是这条通道的两个主变量。. Temperature and time are the two governing variables of this pathway.

三、成因:为什么偏偏是这个碳3. Mechanism: why this particular carbon
把 C7 的四个取代基再看一遍:2-氯苯基是芳环,能与生成的负离子共轭;甲氧羰基是强吸电子基,能稳定 α-碳上的负电荷。两个基团同时作用,使 C7 上的氢比普通 spLook again at the four substituents on C7: the 2-chlorophenyl group is an aromatic ring that can conjugate with the resulting carbanion, and the methoxycarbonyl group is strongly electron-withdrawing and stabilises negative charge on the α-carbon. Acting together, the two groups make the hydrogen on C7 far more acidic than the hydrogen on an ordinary sp3 碳上的氢容易失去得多。碱夺取这个氢,得到平面化的烯醇负离子,负离子两侧都可复质子化,于是 (S) 与 (R) 各得一半。 carbon. A base removes this hydrogen to give a planar enolate, which can be reprotonated from either face, so (S) and (R) are formed in equal amounts.
这不是推测。专利文献里有一条直接的工业证据:为了回收母液中的 (R)-氯吡格雷,做法就是用碱处理使其消旋,再重新拆分;专利明确写到用叔丁醇钾效果优于甲醇钾、乙醇钾,并且要求体系含水量降到很低才有理想的消旋效率This is not speculation. There is direct industrial evidence in the patent literature: to recover (R)-clopidogrel from mother liquors, the material is treated with base to racemise it and then re-resolved; the patent states explicitly that potassium tert-butoxide outperforms potassium methoxide and potassium ethoxide, and that the water content of the system must be reduced substantially to reach acceptable racemisation efficiency[5]。工业上主动做的事,在稳定性里就是被动发生的事——同一套化学,只是方向不同。. What industry does deliberately is what happens passively during stability: the same chemistry, run in a different direction.
由此可以推出几条实操结论。碱性后处理是风险点,游离碱状态停留越久越危险;含水体系会同时推动水解与消旋,两条通道争夺同一个底物;温度每上一个台阶,两条通道一起加速。反过来,成盐(硫酸氢盐)把分子固定成盐形态,既是溶解度需要,也顺带降低了游离碱的暴露时间。这也是为什么本目录里同时收录了游离碱、盐酸盐、苯磺酸盐等多个形态——不同盐型在手性稳定性上的表现不一样,选型阶段值得实测比较。Several practical conclusions follow. Alkaline work-up is a risk point, and the longer the free base persists the greater the danger; aqueous systems drive hydrolysis and racemisation together, with the two channels competing for the same substrate; every increment in temperature accelerates both. Conversely, salt formation fixes the molecule as the bisulfate, which serves the solubility requirement and incidentally reduces exposure time as the free base. This is also why the catalogue lists the free base, hydrochloride, besylate and other forms: different salt forms behave differently in chiral stability, and comparing them experimentally at the selection stage is worthwhile.
四、分析方法:系统适用性为什么要用消旋体4. Analytical method: why system suitability needs the racemate
手性方法的第一原则是:证明两个峰能分开,而不是证明一个峰能出来。用单一 (S) 对照品做系统适用性,只能得到一个峰,分离度无从计算;必须用消旋体(本目录杂质 12,CAS 135046-48-9)或 R-异构体加 (S) 对照品的混合溶液,才能给出分离度、拖尾因子与重复性。这是手性方法验证里最常见的形式性缺陷。The first principle of a chiral method is to prove that two peaks resolve, not that one peak appears. System suitability with a single (S) reference standard yields one peak and no calculable resolution; the racemate (Impurity 12 in this catalogue, CAS 135046-48-9) or a mixed solution of the R-enantiomer with the (S) standard is required to deliver resolution, tailing factor and repeatability. Failing this is the most common formal defect in chiral method validation.
固定相上,多糖类氨基甲酸酯型手性柱是这个分子的常规起点,正相或极性有机模式都可以。这里不写具体柱型号与流动相比例——设备与柱批差异大,照抄往往分不开。能写进资料的是选择依据:分子无强酸强碱基团、只有一个手性中心、紫外吸收弱,依靠氢键与 π-π 作用识别构型,检测端用低波长或质谱补灵敏度。For the stationary phase, polysaccharide carbamate chiral columns are the conventional starting point for this molecule, in normal-phase or polar organic mode. Specific column models and mobile-phase ratios are deliberately omitted here, because equipment and column-batch differences are large and copied conditions often fail to resolve. What can go into a dossier is the rationale: the molecule has no strongly acidic or basic groups, a single stereocentre and weak UV absorption, recognises configuration through hydrogen bonding and π-π interaction, and needs low-wavelength detection or mass spectrometry to recover sensitivity.
检测波长是第二个坑。氯吡格雷的生色团是噻吩环与苯环,最大吸收偏短波,低波长下基线噪声大、辅料干扰重;含量测定用的波长未必适合手性纯度。灵敏度不够时改用 LC-MS/MS,用母体与特征碎片做 MRM,定量限可以压得很低。代价是基质效应与离子抑制要专门考察。Detection wavelength is the second trap. Clopidogrel's chromophores are the thiophene and benzene rings, whose maximum absorption lies at short wavelength, where baseline noise is high and excipient interference severe; the wavelength used for assay is not necessarily suitable for chiral purity. Where sensitivity is insufficient, switch to LC-MS/MS with MRM transitions of the parent and a characteristic fragment, which pushes the limit of quantitation very low, at the cost of having to investigate matrix effects and ion suppression specifically.
样品处理要写进 SOP:供试液避免碱性环境、配制后低温放置、即配即进;自动进样器若不能控温,长序列要把手性样品排在前面。这些不是洁癖——按 7–12 天的半衰期,一个室温过夜序列对 (R) 的贡献虽然不大,但足以落在方法验证的重复性区间里,让人误判方法精密度。Sample handling belongs in the SOP: keep sample solutions away from alkaline conditions, hold them cold after preparation, inject promptly; if the autosampler cannot be temperature-controlled, place chiral samples early in long sequences. This is not fussiness: with a 7–12 day half-life, the contribution of one overnight sequence at room temperature to (R), though small, is enough to fall inside the repeatability window of method validation and cause the precision to be misjudged.

五、限度与申报:手性纯度要单列一项考察5. Limits and filing: chiral purity needs its own test item
手性杂质没有独立的阈值体系,按一般有机杂质管理:ICH Q3A 报告阈值 0.05%、鉴定阈值 0.10%Chiral impurities have no separate threshold system and are managed as ordinary organic impurities: ICH Q3A reporting threshold 0.05%, identification threshold 0.10%[6]。实操上它几乎总被单列成「光学纯度」检查项,因为常规反相方法根本测不到——两个对映体在非手性柱上是同一个峰。限度可以借用框架,方法不能。. In practice it is almost always set up as a separate optical purity test item, because a conventional reversed-phase method cannot detect it at all: the two enantiomers are one peak on an achiral column. The framework for limits can be borrowed; the method cannot.
申报资料最容易缺三处:只有有关物质方法没有手性方法,或有方法却拿不出系统适用性用消旋体的证据;限度只写一个数字、不说明依据(各论要求、实测能力、稳定性支持,是哪一个);稳定性方案把手性纯度漏掉,只在 0 月做一次。第三处最致命——消旋是时间与温度的函数,一次 0 月数据什么也证明不了。Three gaps are most common in dossiers: a related-substances method with no chiral method, or a chiral method without evidence that the racemate was used for system suitability; a limit stated as a bare number with no basis given (monograph requirement, measured capability or stability support, which one?); and a stability protocol that omits chiral purity or tests it only at month 0. The third is the most damaging, since racemisation is a function of time and temperature and a single month-0 data point proves nothing.
稳定性方案建议这样写:长期与加速的每个时间点都测手性纯度;同时做溶液稳定性(供试液在拟定保存条件下的手性纯度变化),把「配好后多久内进样」写成可执行的时限。强制降解也要单独看手性——酸、碱、氧化、高温各档处理后,除看总杂质增长,还要看 (R) 是否增加。碱档尤其要看,因为这条通道本来就是碱促进的。A recommended stability protocol: measure chiral purity at every long-term and accelerated time point; also run solution stability (chiral purity of the sample solution under the proposed storage conditions) and turn "inject within how long after preparation" into an executable time limit. Forced degradation should also look at chirality separately: after acid, base, oxidative and thermal stress, examine not only total impurity growth but whether (R) increases. The base condition especially, because this pathway is base-promoted to begin with.
还有一条容易漏的:亚硝化。本品的四氢吡啶氮是叔胺,不能直接亚硝化,但目录里有一条 N-亚硝基条目挂在 EP 杂质 F 上(CAS 3033746-15-2),提示前体是某个含仲胺的杂质而非母体。按 ICH M7 的框架,这类杂质要单独做风险评估与限度折算One more item is easily missed: nitrosation. The tetrahydropyridine nitrogen of the parent is tertiary and cannot be nitrosated directly, but the catalogue carries an N-nitroso entry attached to EP Impurity F (CAS 3033746-15-2), indicating that the precursor is a secondary-amine-containing impurity rather than the parent. Under the ICH M7 framework such impurities need their own risk assessment and limit derivation[7]。它和手性无关,但同属这个品种绕不开的两条线。. It has nothing to do with chirality, but both are unavoidable lines for this substance.

下面这组数据来自 CDE 公开受理记录,用来说明这个品种在国内的申报密度,不作为获批依据The following data come from public CDE acceptance records and illustrate the filing density for this substance in China; they are not evidence of approval[8]。
六、横向对照:手性负担由三个变量决定,不由「几个中心」决定6. Cross-comparison: chiral burden is set by three variables, not by the number of centres
把同类品种摆在一起看,会发现「手性中心数量」是最不可靠的一个判据。真正决定工作量的是三个变量:手性中心有几个、上市的是单一对映体还是消旋体、以及这个分子在体外或体内会不会自发消旋。Place similar substances side by side and the count of stereocentres turns out to be the least reliable criterion. The real determinants of workload are three: how many stereocentres there are, whether the marketed form is a single enantiomer or a racemate, and whether the molecule racemises spontaneously in vitro or in vivo.
| 品种Product | 手性中心Stereocentres | 上市形态Marketed form | 手性风险要点Key chiral risk |
|---|---|---|---|
| 硫酸氢氯吡格雷Clopidogrel bisulfate | 1 | 单一对映体Single enantiomer | 苄位酯碳,碱促进消旋Benzylic ester carbon; base-promoted racemisation |
| 替格瑞洛Ticagrelor | 多个Multiple | 单一对映体Single enantiomer | 非对映体组合多,方法负担重Many diastereomeric combinations; heavy method burden |
| 艾司奥美拉唑钠Esomeprazole sodium | 1 | 单一对映体(手性切换)Single enantiomer (chiral switch) | 亚砜氮手性,酸中易消旋Sulfoxide nitrogen chirality; racemises readily in acid |
| 布洛芬Ibuprofen | 1 | 消旋体Racemate | 体内单向转化,对映体不是杂质Unidirectional in vivo conversion; the enantiomer is not an impurity |
| 噻氯匹定Ticlopidine | 0 | 非手性Achiral | 无手性负担No chiral burden |
表注:手性中心数与上市形态依各品种结构及现行各论,具体以药典正文为准。Table note: stereocentre counts and marketed forms follow each substance's structure and current monograph; the pharmacopoeial text prevails.
两类不能类比的要单独说。布洛芬以消旋体上市,体内 (R) 向 (S) 的单向转化是药理过程的一部分,对映体根本不是杂质,把它搬到氯吡格雷上会得出完全相反的结论。Two non-analogous classes deserve separate mention. Ibuprofen is marketed as the racemate and its unidirectional in vivo conversion of (R) to (S) is part of its pharmacology, so the enantiomer is not an impurity at all; transplanting that logic to clopidogrel produces exactly the opposite conclusion. 噻氯匹定Ticlopidine↗没有手性中心,是本品的前代药物,拿它的杂质谱套过来会漏掉一整条手性线。 has no stereocentre and is the predecessor drug of this substance; borrowing its impurity profile would miss an entire chiral line. 替格瑞洛Ticagrelor↗与 and the 艾司奥美拉唑Esomeprazole↗虽同为单一对映体,但一个是多中心、一个是亚砜氮手性,机理不同:方法可借鉴思路,限度与稳定性结论不能搬。 is marketed as a single enantiomer too, but one is multi-centre and the other is sulfoxide nitrogen chirality, so the mechanisms differ: the approach can be borrowed, the limits and stability conclusions cannot.
七、五个常见误区7. Five common misconceptions
- 「只有一个手性中心,手性负担很轻」。"One stereocentre means a light chiral burden."中心数量与工作量不成正比。本品只有一个中心,却因为苄位酯碳的消旋性,稳定性方案里必须单列手性纯度考察项。 The number of centres is not proportional to the workload. This substance has one centre, yet because its benzylic ester carbon racemises, the stability protocol must include a separate chiral purity item.
- 「R 异构体只是拆分残留」。"The R-enantiomer is just resolution residue."拆分残留只是来源之一。溶液中的非酶促消旋是第二个来源,靠增加重结晶解决不了。 Resolution residue is only one source. Non-enzymatic racemisation in solution is the second, and more recrystallisation will not fix it.
- 「系统适用性用 (S) 对照品就行」。"The (S) standard is enough for system suitability."单一对映体只有一个峰,算不出分离度。必须用消旋体(杂质 12)或 R 异构体与 (S) 的混合液。 A single enantiomer gives one peak and no calculable resolution. Use the racemate (Impurity 12) or a mixture of the R-enantiomer with the (S) standard.
- 「有关物质合格就说明手性没问题」。"Passing related substances means the chirality is fine."非手性柱上两个对映体是同一个峰,有关物质方法在原理上就看不到手性杂质。 On an achiral column the two enantiomers are the same peak, so a related-substances method cannot see chiral impurities in principle.
- 「稳定性 0 月测一次手性就够了」。"One chiral test at month 0 of stability is enough."消旋是时间与温度的函数,一次数据什么也证明不了。每个时间点都要测,并配套做溶液稳定性。 Racemisation is a function of time and temperature and one data point proves nothing. Test at every time point and pair it with solution stability.
本目录收录硫酸氢氯吡格雷相关条目 This catalogue contains 111 条(含本体与 83 个编号杂质),其中与手性直接相关的是消旋体(杂质 12,CAS 135046-48-9)、R-异构体(杂质 38,EP 杂质 E 的 R 构型,CAS 444728-15-8)与 EP 杂质 E 的对映体混合物(杂质 40,CAS 90055-68-8),另有水解产物 EP 杂质 A 与 N-亚硝基 EP 杂质 F 的衍生物,可用于手性方法开发、分离度验证与稳定性考察项设置: entries (including the parent and 83 numbered impurities). Those directly relevant to chirality are the racemate (Impurity 12, CAS 135046-48-9), the R-enantiomer (Impurity 38, the R configuration of EP Impurity E, CAS 444728-15-8) and the enantiomeric mixture of EP Impurity E (Impurity 40, CAS 90055-68-8); there is also the hydrolysis product EP Impurity A and the N-nitroso EP Impurity F derivative. All support chiral method development, resolution verification and setting up stability test items: → 查看硫酸氢氯吡格雷全部条目→ View all clopidogrel bisulfate entries
常见问题(FAQ)Frequently asked questions (FAQ)
氯吡格雷的 R 异构体一定要控制吗?Must the clopidogrel R-enantiomer be controlled?
消旋为什么会发生?是酶促的吗?Why does racemisation happen, and is it enzymatic?
为什么消旋半衰期要以天计?对实验有什么影响?Why is the racemisation half-life measured in days, and what does that mean for experiments?
手性方法的系统适用性为什么必须用消旋体?Why must system suitability for a chiral method use the racemate?
手性杂质的限度依据是什么?What is the basis for chiral impurity limits?
强制降解要看手性吗?Should forced degradation look at chirality?
布洛芬的手性经验能套过来吗?Can ibuprofen's chiral experience be transferred here?
这个品种的亚硝胺风险和手性有关吗?Is the nitrosamine risk for this substance related to chirality?
相关品种与对照品Related drug substances and reference standards
- 硫酸氢氯吡格雷 / Clopidogrel BisulfateClopidogrel Bisulfate(共 111 个杂质/衍生物条目)(111 impurity and derivative entries in total)
- 氯吡格雷 / ClopidogrelClopidogrel(共 8 个杂质/衍生物条目)(8 impurity and derivative entries in total)
- 替格瑞洛 / TicagrelorTicagrelor(共 199 个杂质/衍生物条目)(199 impurity and derivative entries in total)
- 噻氯匹定 / TiclopidineTiclopidine(共 16 个杂质/衍生物条目)(16 impurity and derivative entries in total)
- 普拉格雷 / PrasugrelPrasugrel(共 80 个杂质/衍生物条目)(80 impurity and derivative entries in total)
参考资料与来源References and sources
- Profiles of Drug Substances, Excipients and Related Methodology(Elsevier,Brittain 主编)《Clopidogrel Bisulfate》专论(含立体化学、活性对映体、溶解度与已知杂质;出版社站点拒绝自动访问,故仅列名称)Profiles of Drug Substances, Excipients and Related Methodology (Elsevier, ed. Brittain), monograph Clopidogrel Bisulfate (stereochemistry, active enantiomer, solubility and known impurities; the publisher site blocks automated access, so the name is listed only)
- Drug Metabolism and DispositionReist M., Roy-de Vos M., Montseny J.P. 等《Very Slow Chiral Inversion of Clopidogrel in Rats: A Pharmacokinetic and Mechanistic Investigation》,2000 年第 28 卷(PMID 11095576;非酶促消旋半衰期 7–12 天、(S)-羧酸 45 天构型稳定、大鼠体内 4–8% (R)-酸)Drug Metabolism and Disposition, Reist M., Roy-de Vos M., Montseny J.P. et al., "Very Slow Chiral Inversion of Clopidogrel in Rats: A Pharmacokinetic and Mechanistic Investigation", 2000, Vol. 28 (PMID 11095576; non-enzymatic racemisation half-life 7–12 days, (S)-carboxylic acid configurationally stable for 45 days, 4–8% (R)-acid in rats)
- 中国药典委员会,Chinese Pharmacopoeia Commission, 《中国药典》硫酸氢氯吡格雷各论Chinese Pharmacopoeia, monograph on Clopidogrel Bisulfate,访问日期 2026-10-21, accessed 2026-10-21
- The Journal of Pediatric Pharmacology and Therapeutics,《Chiral Stability of an Extemporaneously Prepared Clopidogrel Bisulfate Oral Suspension》(PMC3998964;冷藏与室温下 2 个月的对映体变化)"Chiral Stability of an Extemporaneously Prepared Clopidogrel Bisulfate Oral Suspension" (PMC3998964; enantiomeric change over 2 months refrigerated and at room temperature),访问日期 2026-10-21, accessed 2026-10-21
- 美国专利商标局美国专利 US 7,259,261《Racemization and enantiomer separation of clopidogrel》(碱促进消旋的工业实例)USPTO patent US 7,259,261, "Racemization and enantiomer separation of clopidogrel" (industrial example of base-promoted racemisation)
- ICH,ICH Q3A(R2)《新原料药中的杂质》ICH Q3A(R2) Impurities in New Drug Substances,访问日期 2026-10-21, accessed 2026-10-21
- ICH,ICH M7(R2)《评估和控制药物中 DNA 反应性(致突变)杂质以限制潜在致癌风险》ICH M7(R2) Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals to Limit Potential Carcinogenic Risk,访问日期 2026-10-21, accessed 2026-10-21
- 国家药品监督管理局药品审评中心(CDE),Center for Drug Evaluation (CDE), NMPA, 受理品种信息公开(硫酸氢氯吡格雷)public acceptance information (clopidogrel bisulfate),访问日期 2026-10-21, accessed 2026-10-21
说明:本文为 CATO 佳途技术团队原创整理,其中引用的法规、药典与公开文献内容已在上方标注来源,仅用于技术交流与检索参考,不构成质量标准或法规建议;具体品种的检测方法、限值与申报要求,请以现行法规、药典正文及官方发布为准。Note: this article was compiled by the CATO technical team. Regulatory, pharmacopoeial and public literature content cited has been sourced above and is provided for technical exchange and search reference only; it does not constitute a quality specification or regulatory advice. For the test methods, limits and filing requirements of any specific product, the current regulations, pharmacopoeial monographs and official publications prevail.
本站产品信息仅供科研检索与选型参考,不作为质量标准依据;技术参数、纯度与结构确证以随货 COA 及我方书面确认为准。本文涉及的产品均为科研用途,不用于人体或动物诊断、治疗。Product information on this site is for scientific search and selection reference only and is not a quality specification; technical data, purity and structural confirmation are governed by the shipped COA and our written confirmation. All products mentioned are for research use only and are not intended for human or animal diagnosis or treatment.